Search

Displaying results 491 - 500 of 10000 in total
  1. Drug

    Ginsenoside B2

    go.drugbank.com/drugs/DB14815
    Investigational

    Ginsenoside B2 is under investigation in clinical trial NCT00781534 (A Clinical Trial of Ginseng in Diabetes).

  2. Drug

    SB-649868

    go.drugbank.com/drugs/DB14822
    Investigational

    SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  3. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  4. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    (IL-6) blockers, and tumor necrosis factor (TNF) inhibitors. … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring
  5. Drug

    Tibulizumab

    go.drugbank.com/drugs/DB14848
    Investigational

    Tibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).

  6. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).

  7. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). … [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval.

    Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Lymphocyte Activation Gene-3 Blocker
  8. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination … With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).

    Synonyms: Myrcludex B
  9. Drug

    2-(aminomethyl)phenol

    go.drugbank.com/drugs/DB14855
    Investigational

    2-(aminomethyl)phenol is under investigation in clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study in Older Adults).

    Synonyms: 2 HOBA, 2-HOBA
  10. Drug

    Avadomide

    go.drugbank.com/drugs/DB14857
    Investigational

    Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 3-(5-Amino-2-methyl-4-oxo-4H-quinazolin-3-yl)piperidine-2,6-dione